

Paris, July 8, 2014



Healthcare: Air Liquide continues its development with an acquisition in the French overseas departments and territories

Increasing life expectancy and the rise in chronic diseases are major public health issues. Air Liquide **is continuing to develop its home healthcare activity in France** with the acquisition of **SEPRODUM**, a key player in home healthcare and monitoring of patients with chronic diseases in the **French overseas departments and territories**.

Created in 2003, SEPRODUM has nearly 90 employees, caring for **4,500 patients** at home in Reunion, Mayotte, Guadeloupe, and New Caledonia.

SEPRODUM is **recognised for the quality** of its care for patients that need **respiratory assistance at home**, in particular oxygen therapy, mechanical ventilation and the treatment of sleep apnea. SEPRODUM also cares for patients that require **treatment by infusion therapy** and **enteral nutrition** at home. And finally, it also **supplies** and **distributes medical equipment** directly to patients' homes.

Air Liquide is favouring **continuity for the company's management** with Jean-Philippe Rouquié, backed by the expertise and commitment of his teams.

Pascal Vinet, Vice President, Healthcare Global Operations and member of the Air Liquide group's Executive Committee, commented: ***"This acquisition completes our service offering in French overseas departments and territories. With the integration of highly trained teams dedicated to patient care, our home healthcare service offering in France will be reinforced."***

Air Liquide Healthcare

supplies **medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients**.

In 2013, it served over **7,500 hospitals** and more than **1 million patients at home** throughout the world.

The Group's Healthcare business reached **€ 2,689 million** in revenues in **2013**, with the support of its **12,000 employees**.

The Home Healthcare business

Air Liquide, **European leader and 3rd worldwide in home healthcare**, provides home healthcare services in compliance with medical prescription for patients suffering from chronic diseases such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea and diabetes. These home healthcare services are being developed in addition to hospital care, enabling patients to enjoy better quality of life and local authorities to reduce costs. Home healthcare represents **48% of Air Liquide's revenue in Healthcare in 2013**.

CONTACTS

Corporate Communications

Garance Bertrand
+ 33 (0)1 40 62 59 62
Anne Michaud
+ 33 (0)1 40 62 50 59

Investor Relations

Virginia Jeanson
+33 (0)1 40 62 57 37
Annie Fournier
+33 (0)1 40 62 57 18

Air Liquide Healthcare Communication

Muriel Doucet
+ 33 (0)1 49 69 46 46

World leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with more than 50,000 employees and serves more than 2 million customers and patients. Oxygen, nitrogen and hydrogen have been at the core of the Group's activities since its creation in 1902. Air Liquide's ambition is to be the leader in its industry, delivering long-term performance and acting responsibly.

Air Liquide ideas create value over the long term. At the core of the company's development are the commitment and constant inventiveness of its people.

Air Liquide anticipates the challenges of its markets, invests locally and globally, and delivers high-quality solutions to its customers and patients, and the scientific community.

The company relies on competitiveness in its operations, targeted investments in growing markets and innovation to deliver profitable growth over the long-term.

Air Liquide's revenues amounted to € 15.2 billion in 2013, and its solutions that protect life and the environment represented around 40% of sales. Air Liquide is listed on the Paris Euronext stock exchange (compartment A) and is a member of the CAC 40 and Dow Jones Euro Stoxx 50 indexes.